



# SUVEN Life Sciences

## News Release

**HYDERABAD, INDIA (2 Feb 2023)** -- SUVEN Life Sciences Limited ("Suven") today announced unaudited financial results for the quarter ended 31 Dec 2022. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 2 Feb 2023.

### CONSOLIDATED STATEMENT OF OPERATIONS

INR Million, except EPS

	Quarter ended			Period ended		Year ended
	31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22
Revenue	52.07	45.93	45.74	137.75	91.06	134.46
R&D and Operational expenses	545.88	260.85	369.12	1,052.92	1,102.96	1,342.33
Depreciation and Amortisation	16.71	16.20	12.22	48.71	32.91	43.93
Finance cost	0.64	0.69	1.30	2.35	4.32	5.30
Total expenses	563.23	277.74	382.64	1,103.98	1,140.19	1,391.57
Exceptional items (insurance claim received)	-	-	-	60.00	37.16	37.16
Tax	-	-	-	-	-	-
Profit/(Loss) After Tax for the period/year	(511.15)	(231.82)	(336.90)	(906.23)	(1,011.97)	(1,219.95)
Other comprehensive income	(0.38)	(0.38)	(1.18)	(1.13)	(3.54)	(1.51)
Total comprehensive income	(511.53)	(232.19)	(338.08)	(907.36)	(1,015.51)	(1,221.46)
Paid up equity capital	218.07	145.38	127.28	218.07	127.28	145.38
Earnings per share of Rs.1 each (EPS)	(2.90)	(1.51)	(2.50)	(5.46)	(7.51)	(9.05)

- (a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.
- (b) The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.
- (c) The Company has allotted 72,691,239 equity shares amounting to Rs.399.80 Crores through rights issue on November 16, 2022. The EPS (Basic and Diluted) of the corresponding periods have been adjusted appropriately for the bonus element in respect of rights issue made.
- (d) Clinical development pipeline:
- SUVN-502 (Masupirdine) – Initiated phase 3 study for Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; Enrolling patients in sites in US. Expected completion by March 2025.
  - SUVN-G3031 (Samelisant) – Ongoing phase 2 study on Narcolepsy in North America; expected completion by June/July 2023. 164 patients randomized and 128 completed.
  - SUVN-D4010 (Usmarapride) – Completed phase 1 study, ready for phase 2
  - SUVN-911 (Ropanicant) – Completed phase 1 study, ready for phase 2
- (e) Since last reporting period, the Company has been granted 15 patents for its innovative drug discovery covering ARIPO, Brazil, Canada, China, Israel, Japan, Mexico, Singapore, Sri Lanka, South Africa and USA.

For more information on Suven please visit our Web site at <http://www.suven.com>

#### Risk Statement:

Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances, and continued success in growth of revenue that may make our products/services offerings less competitive.

CIN: L24110TG1989PLC009713

6/F, Serene Chambers, Rd#7, Banjara Hills Hyderabad 500034, India  
Tel: 9140 2354 1142 Fax: 9140 2354 1152 Email: [info@suven.com](mailto:info@suven.com)